BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan
· Delayed Price · Currency is TWD 36.40
+0.90 (2.54%)
Mar 10, 2026, 11:04 AM CST
BioGend Therapeutics Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 217.9 | 219.02 | 330.51 | 163.64 | 136.32 | Upgrade
|
| Short-Term Investments | 300 | 400 | 393.76 | 329.76 | 552.96 | Upgrade
|
| Cash & Short-Term Investments | 517.9 | 619.02 | 724.27 | 493.4 | 689.28 | Upgrade
|
| Cash Growth | -16.34% | -14.53% | 46.79% | -28.42% | 34.36% | Upgrade
|
| Accounts Receivable | 58.96 | 47.36 | 26.69 | 11.27 | 5.05 | Upgrade
|
| Other Receivables | 2.61 | 33.37 | 30.67 | 28.25 | 23.61 | Upgrade
|
| Receivables | 61.56 | 80.72 | 57.36 | 39.52 | 28.66 | Upgrade
|
| Inventory | 20.52 | 15.96 | 16.55 | 4.9 | 9.03 | Upgrade
|
| Prepaid Expenses | 36.45 | 2 | 3 | 4.07 | 7.57 | Upgrade
|
| Total Current Assets | 636.43 | 717.7 | 801.18 | 541.89 | 734.54 | Upgrade
|
| Property, Plant & Equipment | 43.11 | 49.57 | 56.2 | 34.01 | 8.89 | Upgrade
|
| Long-Term Investments | 7.65 | 8.33 | 20.34 | 10 | - | Upgrade
|
| Goodwill | - | 17.09 | 17.09 | 17.09 | 17.09 | Upgrade
|
| Other Intangible Assets | 90.34 | 114.07 | 151.04 | 210.95 | 261.92 | Upgrade
|
| Other Long-Term Assets | 37.85 | 5.94 | 4.64 | 7.89 | 1.42 | Upgrade
|
| Total Assets | 815.38 | 912.7 | 1,050 | 821.82 | 1,024 | Upgrade
|
| Accounts Payable | 2.09 | 4.22 | 2.16 | 2.08 | 0.49 | Upgrade
|
| Accrued Expenses | - | 20.61 | 16.57 | 17.22 | 14.39 | Upgrade
|
| Current Portion of Leases | 3.73 | 3.59 | 3.65 | 3.49 | 3.94 | Upgrade
|
| Other Current Liabilities | 30.35 | 4.81 | 23.87 | 9.07 | 6.3 | Upgrade
|
| Total Current Liabilities | 36.16 | 33.23 | 46.25 | 31.86 | 25.13 | Upgrade
|
| Long-Term Leases | 2.85 | 5.84 | 9.44 | 12.28 | 0.48 | Upgrade
|
| Long-Term Unearned Revenue | - | - | 2.5 | 2.5 | 2.5 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 18.73 | 27.13 | 35.52 | 43.92 | 52.31 | Upgrade
|
| Total Liabilities | 57.74 | 66.19 | 93.71 | 90.56 | 80.42 | Upgrade
|
| Common Stock | 1,244 | 1,243 | 1,231 | 1,031 | 1,031 | Upgrade
|
| Additional Paid-In Capital | - | - | - | - | 212.85 | Upgrade
|
| Retained Earnings | -482.93 | -398.32 | -281.85 | -325.52 | -353.91 | Upgrade
|
| Comprehensive Income & Other | -18.54 | -26.58 | -7.96 | -2.38 | -2.16 | Upgrade
|
| Total Common Equity | 742.09 | 817.67 | 940.96 | 702.86 | 887.54 | Upgrade
|
| Minority Interest | 15.55 | 28.84 | 15.81 | 28.4 | 55.91 | Upgrade
|
| Shareholders' Equity | 757.64 | 846.51 | 956.77 | 731.27 | 943.45 | Upgrade
|
| Total Liabilities & Equity | 815.38 | 912.7 | 1,050 | 821.82 | 1,024 | Upgrade
|
| Total Debt | 6.58 | 9.43 | 13.09 | 15.77 | 4.42 | Upgrade
|
| Net Cash (Debt) | 511.33 | 609.59 | 711.18 | 477.64 | 684.86 | Upgrade
|
| Net Cash Growth | -16.12% | -14.28% | 48.90% | -30.26% | 33.49% | Upgrade
|
| Net Cash Per Share | 4.17 | 4.95 | 5.91 | 4.63 | 6.76 | Upgrade
|
| Filing Date Shares Outstanding | 121.26 | 124.26 | 123.08 | 103.08 | 103.08 | Upgrade
|
| Total Common Shares Outstanding | 121.26 | 124.26 | 123.08 | 103.08 | 103.08 | Upgrade
|
| Working Capital | 600.27 | 684.47 | 754.93 | 510.03 | 709.42 | Upgrade
|
| Book Value Per Share | 6.12 | 6.58 | 7.65 | 6.82 | 8.61 | Upgrade
|
| Tangible Book Value | 651.75 | 686.51 | 772.83 | 474.82 | 608.52 | Upgrade
|
| Tangible Book Value Per Share | 5.37 | 5.52 | 6.28 | 4.61 | 5.90 | Upgrade
|
| Machinery | - | 31.6 | 31.19 | 24.66 | 24.55 | Upgrade
|
| Construction In Progress | - | - | 37.57 | 14.91 | - | Upgrade
|
| Leasehold Improvements | - | 38.15 | 0.34 | 0.34 | 0.34 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.